transcon tlr7/8 agonist
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 18, 2021 (NCT04799054)
Timeline
Indications
Mechanism of action
- Toll-like receptor 8AGONIST
TLR8 agonist
- Toll-like receptor 7AGONIST
TLR7 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05980598 | Phase 2 | Sep 29, 2023 | Ascendis Pharma, Inc. |
| NCT04799054 | Phase 1/Phase 2 (Phase 2) | Mar 18, 2021 | Antengene Corporation, Ascendis Pharma, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascendis Pharma, Inc. | For profit | 2 | 2 | 1 | 2021 |
| Antengene Corporation | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1